Why the study?
Does sacubitril/valsartan increase ANP concentrations and is this associated with reverse cardiac remodeling in patients with HFrEF?
Does sacubitril/valsartan increase ANP concentrations and is this associated with reverse cardiac remodeling in patients with HFrEF?
Initiation of sacubitril/valsartan in HFrEF doubles ANP concentrations, an early increase that correlates with the magnitude of subsequent reverse cardiac remodeling.
Answers are grounded in this paper and cite their sources.
Early ANP rise may identify greater remodeling response to sacubitril/valsartan in HFrEF; hypothesis-generating and requires prospective validation.
Concentrations of ANP doubled after initiation of sacubitril/valsartan in patients with HFrEF. Larger early increases in ANP were associated with a greater magnitude of subsequent reverse cardiac remodeling. (Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes [PROVE-HF]; NCT02887183).
No takes yet. Share an insight, caveat, or question.
Murphy et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: